Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.

Nat Commun · 2022 · PMC8921328 · PMID 35289329

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

a nonsignificant trendp = 0.13not close (p > 0.1)

When the modified percent score (MPS) was assessed as a continuous scale, we found a nonsignificant trend of higher MPS in patients with PFS-6 ( p = 0.13, Supplemental Table 6 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.